Cargando…

MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer

BACKGROUND: Altered cellular metabolism is a hallmark of cancer and some are reliant on glutamine for sustained proliferation and survival. We hypothesise that the glutamine–proline regulatory axis has a key role in breast cancer (BC) in the highly proliferative classes. METHODS: Glutaminase (GLS),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Craze, Madeleine L, Cheung, Hayley, Jewa, Natasha, Coimbra, Nuno D M, Soria, Daniele, El-Ansari, Rokaya, Aleskandarany, Mohammed A, Wai Cheng, Kiu, Diez-Rodriguez, Maria, Nolan, Christopher C, Ellis, Ian O, Rakha, Emad A, Green, Andrew R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785743/ https://www.ncbi.nlm.nih.gov/pubmed/29169183 http://dx.doi.org/10.1038/bjc.2017.387

Ejemplares similares

The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer
por: Masisi, Brendah K., et al.
Publicado: (2021)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer
por: Ansari, Rokaya El, et al.
Publicado: (2019)

The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours
por: El Ansari, Rokaya, et al.
Publicado: (2018)

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes
por: El Ansari, Rokaya, et al.
Publicado: (2018)

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes
por: Joseph, Chitra, et al.
Publicado: (2018)

Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer
por: Morotti, Matteo, et al.
Publicado: (2020)

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers
por: Klimov, Sergey, et al.
Publicado: (2017)

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer
por: El Ansari, Rokaya, et al.
Publicado: (2020)

Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2017)

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2021)

Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer
por: Althobiti, Maryam, et al.
Publicado: (2021)

Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2020)

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2012)

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers
por: Sung, Hyuna, et al.
Publicado: (2016)

Proline metabolism and cancer: emerging links to glutamine and collagen
por: Phang, James M., et al.
Publicado: (2015)

Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers
por: Green, A R, et al.
Publicado: (2013)

The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer
por: Otto, N, et al.
Publicado: (2012)

Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype
por: Kristiansen, G, et al.
Publicado: (2010)

ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC
por: Griffin, Nicolas I., et al.
Publicado: (2016)

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
por: Wang, L L, et al.
Publicado: (2015)

Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
por: Einama, T, et al.
Publicado: (2012)

Phenotypic characterisation of breast cancer: the role of CDC42
por: Chrysanthou, Eleni, et al.
Publicado: (2017)

Proline oxidase controls proline, glutamate, and glutamine cellular concentrations in a U87 glioblastoma cell line
por: Cappelletti, Pamela, et al.
Publicado: (2018)

Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network
por: Boult, J K R, et al.
Publicado: (2008)

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair
por: Johnston, Simon J., et al.
Publicado: (2018)

Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer
por: Grinde, Maria T., et al.
Publicado: (2019)

Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas
por: Seo, A N, et al.
Publicado: (2014)

Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours
por: Caiazza, F, et al.
Publicado: (2011)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer
por: Alshareeda, A T, et al.
Publicado: (2015)

Glutamine on the luminal microbial environment after massive small bowel resection.
por: Choi, Seung Hye, et al.
Publicado: (2002)

Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival
por: Kuang, B-H, et al.
Publicado: (2013)

EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer
por: Soysal, S D, et al.
Publicado: (2013)

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers
por: Aleskandarany, Mohammed, et al.
Publicado: (2015)

Mycobacterium tuberculosis pili (MTP), a putative biomarker for a tuberculosis diagnostic test
por: Naidoo, Natasha, et al.
Publicado: (2014)

Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response
por: Al-kaabi, M M, et al.
Publicado: (2015)

The Splicing Factor Proline-Glutamine Rich (SFPQ/PSF) Is Involved in Influenza Virus Transcription
por: Landeras-Bueno, Sara, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_84f6eikdm71da1q91r629b2jc6